Profil
Michelle Avery is currently working as a Senior Director-Investor Relations at Pandion Therapeutics, Inc. since 2020.
Prior to this, she worked as a Director-Investor Relations at Summit Therapeutics Ltd.
Aktive Positionen von Michelle Avery
| Unternehmen | Position | Beginn |
|---|---|---|
| PANDION THERAPEUTICS, INC. | Investor Relations Kontakt | 01.09.2020 |
Ehemalige bekannte Positionen von Michelle Avery
| Unternehmen | Position | Ende |
|---|---|---|
Summit Therapeutics Ltd.
 Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | Investor Relations Kontakt | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Pandion Therapeutics, Inc.
 Pandion Therapeutics, Inc. BiotechnologyHealth Technology Pandion Therapeutics, Inc. is a clinical stage biopharmaceutical company. It develops Therapeutic Autoimmune reguLatOry proteiN (TALON) drug design and discovery platform, which employ a modular approach to create a pipeline of product candidates using immunomodulatory effector modules that act at known control nodes within the immune network. The company was founded by Dr. Joanne Viney on September 19, 2016 and is headquartered in Watertown, MA. | Health Technology |
